EIKN news

Latest 3 stories · newest Oct 26, 2026

EIKN

EIK1001 in NSCLC shows durable effect and good tolerability

Eikon Therapeutics reported updated clinical data for its TLR7/8 agonist EIK1001. In NSCLC patients, the combination with pembrolizumab and chemotherapy demonstrated a durable effect with an encouraging safety profile, a key differentiator from previous therapies. The company also noted their ongoin…

Legal Oct 26, 2026 sentiment +0.30 SEC filing ↗

EIKN

Eikon presents new PARP and WRN inhibitor data at ESMO

Eikon Therapeutics reported updated data on its PARP1 inhibitors non-brain-penetrant EIK1003 and CNS-penetrant EIK1004, alongside data on WRN helicase inhibitor EIK1005, all showing favorable safety profiles. The release reinforces the company's pipeline potential for 2027.

Other Oct 23, 2026 sentiment +0.40 SEC filing ↗

EIKN

Eikon Therapeutics releases Q2 2026 company update on clinical programs

Eikon Therapeutics issued a quarterly update covering its drug development strategy and platform progress. The filing contains forward-looking statements regarding clinical trials, technology applications, and 2026 milestones for the biotech company.

Other Jun 1, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same EIKN feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/EIKN/newsSTART FREE